Citi initiates coverage on 5 new biotech stocks [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
The firm initiated coverage on Gilead and Vertex with Buy ratings, citing solid growth drivers, while Amgen, Biogen, and Regeneron received Neutral ratings due to certain market challenges and pipeline uncertainties. For Amgen, Citi analysts underscore the potential of its obesity and diabetes drug, MariTide, though the firm remains cautious due to competitive pressures in the GLP-1 market. They believe the company's growth outlook “hinges on MariTide clinical success and to a lesser degree, the trajectory for a number of newer products,” such as Tepezza, Uplizna, Krystexxa, and Imdelltra. Vertex also earned a Buy rating at Citi, primarily due to its leadership in cystic fibrosis and the potential from new therapies, including the vanzacaftor triple combination for CF and suzetrigine for acute pain. “Given consistent growth in CF, with multiple PDUFA dates in early 2025 and a clear path to broader diversification, we are very positive on the growth story for Vertex,” analysts
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- MCK Stock Down Despite Latest Partnership to Boost SCD Treatment [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 48% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/4/24 - Beat
VRTX
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/13/24 - Form 4
- VRTX's page on the SEC website